Pipeline
Our oncology pipeline includes multiple dual-payload immunotherapies and targeted vector immunotherapies.
Our lead candidate, GEN2, carries a proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK) and an immunocytokine, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Our HSV-eTK gene has been engineered in-house for increased cancer cell killing. These therapeutic genes work together to release patient specific neoantigens and induce the immune system to activate a persistent and systemic response against the cancer.
Additional assets are under development for infectious disease applications.
Pipeline
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase I
Candidate
GEN-4035
Indication
Undisclosed